News and Press Releases
Valo Therapeutics is developing a virus-based immunotherapy to defeat cancer
There have been major developments in cancer treatment in recent years. However, treatment of advanced, metastasized tumours remains challenging, and still requires search for new solutions. Valo Therapeutics is currently developing an oncolytic virus-based immunotherapy that is scheduled to enter clinical trials in upcoming years.
Adenoviruses and the immune system join forces against cancer
IDIBELL researchers have developed an oncolytic virus capable of redirecting the patient's immune system against their tumor cells
Immuno-oncology News: Valo Therapeutics Developing Unique Viral-particle Cancer Vaccine
A new cancer vaccine that uses viral particles to trigger strong immune responses against cancer cells is being developed by Valo Therapeutics.
Drug Discovery and Development- "Immunotherapy: Training The Body to Fight Cancer"
Top researchers in the field of immuno-oncology show promising results using peptide / antibody vaccine combination treatments in terminally ill patients with metastatic tumours
Oncolytic Viruses "undervalued" technology with strong growth perspectives
Major acquisitions (>$1bn) have been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment.
Start-Up Oncolytic Virus firm Trieza licenses Abzena antibody
Trieza Therapeutics negotiates an exclusive worldwide license to an antibody sequence generated by Abzena
Viral therapy leaders announce formation of new immunotherapy company
Pioneers in the oncolytic virus and gene therapy fields announce the formation of IGNITE Immunotherapy Inc., a new company focused on oncolytic cancer vaccine discovery and development. The lead investor, Pfizer Inc., will collaborate on IGNITE’s new research program to help discover potential novel vaccinia viruses.